Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.00%
)
US TECH 100
23,263.01
(
-1.06%
)
Dow Jones
46,429.49
(
0.00%
)
Brent Oil
102.07
(
3.33%
)
Bitcoin
69,421.40
(
-2.64%
)
News Focus
News Focus
Post# of 257288
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mskatiescarletohara post# 2105

Thursday, 05/06/2004 12:31:35 PM

Thursday, May 06, 2004 12:31:35 PM

Post# of 257288
Re: DME endpoints:

>> In other words there is no miracle drug out there to affect a change in the FDA's three year stance. <<

Diabetic retinopathy/DME progresses more slowly than AMD –hence the FDA’s requirement for three-year data to support an approval. Shorter trials might be possible if there were reliable surrogate markers, but none have yet been found that correlate to the permanent change in visual acuity.

>> What treatment options are available for DME? <<

The thermal laser, provided that the lesion is not located in the foveal (central) region.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today